Biologics

A new clinical trial, led by the University of Glasgow and NHS Greater Glasgow and Clyde (NHSGGC), hopes to improve treatment options for patients with Crohn’s disease.   The BIOPIC (BIOlogics and Partial enteral nutrition In adults with active ileocolonic Crohn’s disease) study, which is in collaboration with hospitals around Scotland, will evaluate the use […]

This week in drug discovery (26-30 September) News round-up by DDW Editor Reece Armstrong. An interesting week across the board for the pharma sector with the first biologic for severe asthma approved in the EU. Elsewhere researchers have discovered new ways of  identifying cancer cells and a manufacturing system could advance the development and production […]

AstraZeneca’s Tezspire (tezepelumab) has been approved in the European Union as an add-on maintenance treatment in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product.  The approval by the European Commission was based on results from the Pathfinder clinical trial programme, which included […]

A biologic therapy for very young children with moderate to severe eczema (or atopic dermatitis) has been shown to be safe and effective in an international trial. Sponsored by Regeneron and Sanofi, the study of dupilumab in poorly controlled eczema is the first large-scale randomised double-blind trial of a monoclonal antibody for any skin disease […]

The ability to monitor biologic candidates’ propensity towards self-association is critical for predicting whether a therapeutic is likely to aggregate or become difficult to administer due to viscosity. In this app note, read how Merck KGaA uses light scattering measurements to predict how formulations will behave at clinically relevant concentrations and find the optimal formulation […]

This e-book by NanoTemper looks at the workflows researchers are using in the biologics space and the benefits dynamic light scattering (DLS) offers. You will find out: What biologics are and why they’re important How DLS gives you information about your samples and what that data means Tips and considerations when designing your own DLS […]

Drug development technology has evolved rapidly in recent years, and with the industry advancement comes an increased capability of producing high-quality targeted large molecule drugs such as biologics and biosimilars. The significance of biologics is far-reaching, including treatment of rheumatologic diseases, cancer, diabetes and anaemia. The range of therapy modalities is ever-expanding and at present […]

Drug development technology has evolved rapidly in recent years, and with the industry, advancement comes an increased capability of producing high-quality targeted large molecule drugs such as biologics and biosimilars. Since most biologics are large molecules, they may prove challenging to develop and manufacture on the large scale. However, the adoption of automation in the […]

AstraZeneca’s Biologics License Application (BLA) for tremelimumab has been accepted for Priority Review in the US, the company has announced. Tremelimumab is a human monoclonal antibody which AstraZeneca is investigating as a potential therapy for cancers. It works by targeting the activity of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Now, tremelimumab has been accepted for an […]

CAS, a division of the American Chemical Society specialising in scientific information solutions, has launched an expansion of the CAS SciFinder Discovery Platform into life sciences. The enhanced platform includes over two million modified biosequences, 60 years of patent literature, and one of the largest collections of journal information including PubMed’s biomedical and life science […]